Clinical Trial Update: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ruxolitinib phosphate or dasatinib with chemotherapy in relapsed or refractory Philadelphia chromosome-like acute lymphoblastic leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Ruxolitinib phosphate (ruxolitinib phosphate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2022-05-02